A5019152898- Childhood Cancer Survivors' Quality of Life
- Neuroblastoma Research and Treatments
- Neuroendocrine Tumor Research Advances
- Renal and related cancers
- Health Systems, Economic Evaluations, Quality of Life
- Sarcoma Diagnosis and Treatment
- Genomics and Rare Diseases
- Epigenetics and DNA Methylation
- Cancer Genomics and Diagnostics
- Virus-based gene therapy research
- Ethics in Clinical Research
- Medical Imaging and Pathology Studies
- Neurofibromatosis and Schwannoma Cases
- Economic and Financial Impacts of Cancer
- Viral Infections and Immunology Research
- Colorectal and Anal Carcinomas
- Animal Disease Management and Epidemiology
- Lung Cancer Research Studies
- Glioma Diagnosis and Treatment
- Pancreatic and Hepatic Oncology Research
- Protein Tyrosine Phosphatases
- Poxvirus research and outbreaks
- Statistical Methods in Clinical Trials
- Chromatin Remodeling and Cancer
- Ear and Head Tumors
National Cancer Institute
1993-2023
National Institutes of Health
1996-2023
Center for Cancer Research
2021-2023
Vanderbilt University Medical Center
2009
Vanderbilt University
2001
Johns Hopkins University
1989-1991
Rensselaer Polytechnic Institute
1987
Data-driven basic, translational, and clinical research has resulted in improved outcomes for children, adolescents, young adults (AYAs) with pediatric cancers. However, challenges sharing data between institutions, particularly research, prevent addressing substantial unmet needs children AYA patients diagnosed certain Systematically collecting from every child can enable greater understanding of cancers, improve survivorship, accelerate development new more effective therapies. To...
H2dl808 is a deletion mutant of adenovirus type 2 lacking most transcriptional early region E4. In normal host cells this virus displayed complex phenotype that included dramatic reduction in the level cytoplasmic late RNA, corresponding defect protein synthesis, and 5- to 10-fold viral DNA accumulation. H5dl1004 5 also lacks portion It exhibited levels RNAs was somewhat less severe than synthetic but no production DNA. addition accumulation mRNAs, HeLa infected by either or showed...
The RASopathies are a group of disorders due to variations genes associated with the Ras/MAPK pathway. Some include neurofibromatosis type 1 (NF1), Noonan syndrome, syndrome multiple lentigines, cardiofaciocutaneous (CFC) Costello Legius and capillary malformation–arteriovenous malformation (CM‐AVM) syndrome. In combination, frequent genetic disorders. This report summarizes proceedings 4th International Symposium on Genetic Disorders pathway highlights gaps in field. © 2016 Wiley Periodicals, Inc.
Bovine papillomavirus type 1 (BPV-1) is the prototype virus for study of gene regulation. The functions BPV-1 E2 proteins in transcriptional regulation have been well characterized. E1 protein required viral DNA replication and can bind to origin alone or a complex with transactivator protein. In this study, we demonstrated that also involved significantly repressed E2-transactivated transcription from major early promoter P89. This activity consistent elevated level P89 observed open...
CRA6509 The full, final text of this abstract will be available in Part II the 2009 ASCO Annual Meeting Proceedings, distributed onsite at on May 30, 2009, and as a supplement to June 20, issue Journal Clinical Oncology. No significant financial relationships disclose.
Rare tumors account for one fourth of adult tumors; in children, rare represent approximately 15-20% childhood malignancies, thus accounting a significant burden disease. The rarity these individual diseases creates many challenges, from developing thorough understanding the disease pathophysiology, clinical characterization, to conduct meaningful trials and eventually development effective therapies.Despite substantial advances have been made recent years including novel trial designs...
Abstract Rare tumors across the world are lacking adequate knowledge, resources, and community. Through partnership with patients, advocacy organizations, researchers, clinicians, we have developed a comprehensive, longitudinal, prospective, retrospective natural history protocol to collect, analyze, share data on patients rare tumors. A strong collaborative effort is vital ensure success of enrollment, patient engagement, collection, analysis ultimately develop clinical trials improve...
Mutants of adenovirus type 5 (Ad5) that lack early region 4 (E4) are defective in the expression viral late genes. E4 mutants exhibit dramatically reduced levels both cytoplasmic and nuclear RNAs compared to wild-type virus, due principally stability unprocessed RNA nucleus mutant-infected cells. To determine whether products also affect metabolism host infected cells, steady-state beta-actin triose phosphate isomerase (TPI) were measured cytoplasms nuclei HeLa cells by either Ad5 or...
6543 Background: To examine the accrual rates for all phases clinical trials opened at four selected comprehensive cancer centers (CCCs). Methods: Accrual data date ranges was collected non-pediatric following CCCs: Fox-Chase Cancer Center (1/2000–4/2007), Lineberger Comprehensive University of North Carolina (1/2000–12/2005), The Ohio State (1/2000–4/2007) and Vanderbilt-Ingram (1/2001–7/2005). Data were on studies, regardless phase, these institutions. Results: mean number that resulted in...
CRA6509 Background: Post-activation barriers to oncology clinical trial accruals are well documented; however, potential prior opening not. We investigate one such barrier: development time. Methods: National Cancer Institute Therapy Evaluation Program (NCI-CTEP) sponsored trials for all therapeutic, non-pediatric phase I,I/II, II, and III studies activated in an eight year period (2000–2007) were investigated (n=553). Successful those achieving 100% of minimum accrual goal. Time open a...
Abstract Background Chordomas are rare tumors arising from the skull base and spine, with approximately 20 pediatric chordoma cases in Unitedn States per year. The natural history optimal treatment of chordomas, especially poorly differentiated dedifferentiated subtypes, is incompletely understood. Herein, we present findings our first National Cancer Institute (NCI) clinic a retrospective analysis published chordomas (PDC) (DC). Methods Patients less than 40 years old were enrolled on NCI...
The bovine papillomavirus type 1 (BPV-1) long control region (LCR) contains at least three consensus binding sites for the transcription factor Sp1 nucleotides (nt) 7800, 7833 and 7854. A high basal-level P89 expression vector consisting of an origin-deleted LCR fused to chloramphenicol acetyltransferase (CAT) gene was utilized determine role these in regulation from BPV-1 promoter. were capable vitro. Mutation background LCR-CAT or a wild-type construct resulted decreased basal P89. In...
Abstract Understanding of tumor biology and identification effective therapies is lacking for many rare tumors. My Pediatric Adult Rare Tumor (MyPART) network was established to engage patients, advocates, researchers conduct a comprehensive longitudinal Natural History Study Solid Tumors. Through remote or in-person enrollment at the NIH Clinical Center, participants with solid tumors ≥4 weeks old complete standardized medical family history forms, patient reported outcomes, provide tumor,...
CRA6509 Background: Post-activation barriers to oncology clinical trial accruals are well documented; however, potential prior opening not. We investigate one such barrier: development time. Methods: National Cancer Institute Therapy Evaluation Program (NCI-CTEP) sponsored trials for all therapeutic, non-pediatric phase I,I/II, II, and III studies activated in an eight year period (2000–2007) were investigated (n=553). Successful those achieving 100% of minimum accrual goal. Time open a...
Abstract Background: Rare tumors are defined as <15 cases/100,000 people/year and present an unmet need due to lack of effective medical treatments, paucity biospecimens research models, difficulty accruing clinical trials. MyPART (My Pediatric Adult Tumor Network) was established to: 1) engage patients/advocates partners in rare tumor research, 2) provide expertise personalized health care children young adults with tumors, 3) build databases tools advance on new treatments for...
Abstract PURPOSE: Rare cancers (<15 cases per 100,000 people/year) are poorly understood, particularly in Hispanic/Latinx populations. The My Pediatric and Adult Tumor (MyPART) network conducts a Natural History Study of Solid Tumors (NHSRT) to better understand rare tumor biology develop effective therapeutic strategies. We analyzed NHSRT participants. METHODS: Patients any age with solid tumors eligible. All participants complete medical family history forms, patient-reported...
<div>Abstract<p>Understanding of tumor biology and identification effective therapies is lacking for many rare tumors. My Pediatric Adult Rare Tumor (MyPART) network was established to engage patients, advocates, researchers conduct a comprehensive longitudinal Natural History Study Solid Tumors. Through remote or in-person enrollment at the NIH Clinical Center, participants with solid tumors ≥4 weeks old complete standardized medical family history forms, patient reported...
<p>Other health issues reported in 3 or more participants out of 115 respondents by tumor type.</p>
<p><b>A,</b> Number of participants by rare tumor diagnoses (<i>N</i> = 197). <b>B,</b> Diagnoses with only one participant enrolled 1). <b>C,</b> Month enrollment 197 in 2019 and 2020, relative to the start COVID pandemic restrictions at NIHCC March 2020. Clinic cohort patients are shown red field blue.</p>
<p>Tumor-directed treatments.</p>